Enlivex Ltd. (ENLV): Cash & Equivalents
$1.89M
As of 2025-12-31
-66.4%
3-year compound annual growth
-19.7%
5-year compound annual growth
-12.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.89M | -42.6% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $3.30M | +306.0% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $813.0K | -98.4% | 2025-04-30, Balance as of period end |
| 2022-12-31 | $49.95M | +345.9% | 2024-04-30, Balance as of period end |
| 2021-12-31 | $11.20M | +97.5% | 2023-04-10, Balance as of period end |
| 2020-12-31 | $5.67M | +43.7% | 2022-04-29, Balance as of period end |
| 2019-12-31 | $3.95M | -59.4% | 2021-04-30, Balance as of period end |
| 2018-12-31 | $9.74M | +7.8% | 2020-04-30, Balance as of period end |
| 2017-12-31 | $9.03M | +31.5% | 2020-04-30, Balance as of period end |
| 2016-12-31 | $6.87M | -5.7% | 2020-01-23, Balance as of period end |
| 2015-12-31 | $7.29M | -31.2% | 2018-04-23, Balance as of period end |
| 2014-12-31 | $10.58M | n/m | 2017-02-24, Balance as of period end |
| 2013-12-31 | $270.0K | +84.9% | 2016-03-29, Balance as of period end |
| 2012-12-31 | $146.0K | n/a | 2015-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Enlivex Ltd. (ENLV) | 2025-12-31 | $1.89M | -42.6% |
| Insmed Inc (INSM) | 2025-12-31 | $510.44M | -8.0% |
| Alkermes plc. (ALKS) | 2025-12-31 | $388.57M | +33.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $984.65M | +26.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $550.94M | +80.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
Compare ENLV, INSM, ALKS, OPK side by side · Screen every company in Pharmaceutical Preparations ↗